【摘要】 目的 探讨帕博利珠单抗联合靶动脉灌注化疗治疗晚期非小细胞肺癌（NSCLC）的效果及安全性。方法 将60例晚期NSCLC患者随机分为观察组（帕博利珠单抗联合靶动脉灌注化疗）与对照组（靶动脉灌注化疗）。比较两组的治疗效果及安全性。结果 观察组DCR、 ORR高于对照组，治疗后的CEA、 NSE水平低于对照组（P <0.05）。治疗后，两组的CD4~+、 CD8~+、CD4~+/CD8~+降低，且观察组的CD4~+、 CD8~+、 CD4~+/CD8~+低于对照组（P <0.05）。两组的毒副作用发生率比较无统计学差异（P>0.05）。结论 帕博利珠单抗联合靶动脉灌注化疗治疗晚期NSCLC的效果较好，可改善机体免疫状态，安全性较高。更多还原

【Abstract】 Objective To analyze the effect and safety of pembrolizumab combined with target artery infusion chemotherapy in the treatment of advanced non-small cell lung cancer(NSCLC). Methods 60 patients with advanced NSCLC were randomly divided into observation group(pembrolizumab combined with target artery infusion chemotherapy) and control group(target artery infusion chemotherapy). The treatment effect and safety were compared between the two groups. Results The DCR and ORR of the observation group were higher than those of the control group, and the CEA and NSE levels after treatment were lower than those of the control group(P<0.05). After treatment, the CD4+, CD8+and CD4+/CD8+of the two groups decreased, and the CD4+, CD8+and CD4+/CD8+of the observation group were lower than those of the control group(P <0.05). No statistical difference was found in the incidences of toxic and side effects between the two groups(P >0.05). Conclusions Pembrolizumab combined with target artery infusion chemotherapy has better effect in the treatment of advanced NSCLC, which can improve the immune state with higher safety.更多还原